Compare PEB & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEB | URGN |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2009 | 2017 |
| Metric | PEB | URGN |
|---|---|---|
| Price | $11.26 | $21.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $12.28 | ★ $28.50 |
| AVG Volume (30 Days) | ★ 2.0M | 998.4K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,464,126,000.00 | $96,516,000.00 |
| Revenue This Year | $2.32 | $27.96 |
| Revenue Next Year | $2.42 | $123.02 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.99 | ★ 8.00 |
| 52 Week Low | $7.42 | $3.42 |
| 52 Week High | $14.85 | $30.00 |
| Indicator | PEB | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 42.19 |
| Support Level | $10.67 | $21.74 |
| Resistance Level | $11.71 | $30.00 |
| Average True Range (ATR) | 0.34 | 1.56 |
| MACD | 0.02 | -0.72 |
| Stochastic Oscillator | 61.24 | 3.15 |
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.